VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ELCC 2016 | Phase 2 trial of chemotherapy plus gefitinib as first-line treatment for lung adenocarcinoma

Giorgio Scagliotti • 15 Apr 2016
ELCC 2016
Warning: array_filter() expects parameter 1 to be array, bool given in /home/customer/www/vjoncology.com/public_html/wp-content/themes/vj/single.php on line 281

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses a phase 2 trial evaluating the combination of chemotherapy and gefitinib, a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), as first-line treatment for patients with advanced lung adenocarcinoma and activating EGFR mutations.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter